By Bill Murphy
Verax Biomedical Inc., which has developed technology to enable rapid blood tests, has raised $2.78 million, or over 55 percent of a mixed offering of $5 million, from 11 investors, according to an SEC filing.
Principals named in the filing by the Worcester, Mass.-based firm are the following executives:
? CEO James Lousararian;
? Joe Sanders, senior vice president for Marketing and Business Development;
? Nancy Hornbaker, vice president for Regulatory Affairs;
? R. Scott McKenzie, senior vice president of Operations; and
? Greg Lawrence, vice president for Research and Development.
Also named in the filing were the following directors;
? Buzz Benson of Minneapolis-based SightLine Partners;
? Joe Del Guercio of Bethesda, Md.-based Clark Enterprises Inc.;
? Marc Goldberg of Boston-based Bioventures Investors;
? James Koziarz of Midwest Venture Partners; and
? Robert Zieserl of Highland Park, Ill.-based KB Partners.
Lousararian, who began consulting with Verax in the fall of 2005, was named the CEO in February 2006. Prior to joining Verax, he was a consultant for Medtronic Vascular, following that company?s acquisition of Angiolink Corp. in November 2004. Lousararian previously co-founded and led a life sciences startup, AngioLink.
Verax Biomedical enables rapid tests to detect bacterial contaminants in blood components, tissues for transplantation and cellular therapies.